The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.
The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.
At the moment there are no approved medicines to protect from or treat Ebola. Some experimental treatments have reportedly shown encouraging results in the laboratory or in animals, but they have not yet been fully studied in humans.
Over 5,300 cases of Ebola have been reported and more than 2,600 people have died. The current outbreak represents the widest geographical spread of the disease ever reported.
EMA has established a group of European experts with specialized knowledge in vaccines, infectious diseases and clinical trial design to contribute to the global response against Ebola. EMA Executive Director Guido Rasi has asked the Committee for Medicinal Products for Human Use (CHMP) to perform a formal review of the available scientific information; companies are invited to send all available quality, preclinical and clinical data about their treatments under development for review.
The companies identified so far include:
Companies that are not included in the list above but are also developing Ebola treatments are encouraged to contact the EMA. The review will focus on medicines under development that are used to treat people infected with the virus. Vaccines to protect people against contracting the disease and blood therapies involving the blood of survivors of Ebola infection are excluded from this review.
This entry was posted in
Europe
,
Global
,
healthcare
,
Regulatory
and tagged
Ebola
,
EMA
,
European Medicines Association
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
February 7th 2025Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson disease.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.